Last reviewed · How we verify

Curcumin (Turmeric)

Services Institute of Medical Sciences, Pakistan · Phase 3 active Small molecule

Curcumin inhibits multiple inflammatory pathways and transcription factors, particularly NF-κB, reducing pro-inflammatory cytokine production and oxidative stress.

Curcumin inhibits multiple inflammatory pathways and transcription factors, particularly NF-κB, reducing pro-inflammatory cytokine production and oxidative stress. Used for Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Rheumatoid arthritis, Cancer chemoprevention and adjuvant therapy.

At a glance

Generic nameCurcumin (Turmeric)
Also known asTurmeric
SponsorServices Institute of Medical Sciences, Pakistan
Drug classNatural polyphenol / anti-inflammatory agent
TargetNF-κB, multiple cytokines (TNF-α, IL-6, IL-8), reactive oxygen species
ModalitySmall molecule
Therapeutic areaInflammation, Oncology, Gastrointestinal, Rheumatology
PhasePhase 3

Mechanism of action

Curcumin is a polyphenolic compound that acts as a pleiotropic inhibitor of inflammation and oxidative stress. It suppresses NF-κB signaling, downregulates TNF-α, IL-6, and IL-8, and exhibits antioxidant properties through free radical scavenging. These mechanisms underlie its potential therapeutic effects across multiple disease states characterized by chronic inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: